Omega-3 supplements and cardiovascular diseases

Affiliations

¹ Cardiovascular Department, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Section of Cardiovascular Medicine, Center for Outcomes Research and Evaluation (CORE), and Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.

Review

Azin Mohebi-Nejad et al. Tanaffos. 2014.

. 2014;13(1):6-14.

¹ Cardiovascular Department, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
² Section of Cardiovascular Medicine, Center for Outcomes Research and Evaluation (CORE), and Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.

No abstract available

Figures

1. Schultz H. Retail omega-3s sales to hit $34.7 billion in 2016, report predicts. 2012. [cited 2013 September 17]; Available from: http://www.nutraingredients-usa.com/Markets/Retail-omega-3s-sales-to-hit....
1. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012;17(12):1272–82. - PMC - PubMed
1. Cabré E, Mañosa M, Gassull MA. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. Br J Nutr. 2012;107(Suppl 2):S240–52. - PubMed
1. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1(2):182–92. - PubMed
1. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr. 2012;107(Suppl 2):S228–39. - PubMed